Replimune to Present at Two Upcoming Investor Conferences

Replimune Group, Inc., a clinical-stage biotechnology company specializing in oncolytic immunotherapies, has announced its participation in two significant investor conferences. The first event is the Leerink Partners 2026 Global Healthcare Conference, where a fireside chat featuring Replimune's management team will take place on March 9, 2026, at 2:20 PM EDT. This will be followed by the Jefferies 2026 Biotech on the Beach Summit on March 10, 2026, featuring one-on-one meetings for investors.

Replimune, founded in 2015 and headquartered in Woburn, Massachusetts, aims to revolutionize cancer treatment through its innovative RPx platform, which utilizes a potent herpes simplex virus type 1 (HSV-1) backbone designed to maximize immunogenic cell death. The platform's unique approach allows for the direct and selective virus-mediated destruction of tumors, leading to the release of tumor-derived antigens. This process alters the tumor microenvironment, fostering a robust systemic immune response against cancer.

The company anticipates that its RPx product candidates, which can potentially work synergistically with various established and experimental cancer therapies, will provide flexible development pathways whether used independently or in combination with other treatment modalities.

Webcasts of the fireside chat will be accessible on Replimune's website, with recordings available for 30 days following the events, ensuring shareholders and interested parties can engage with the company's insights and developments even if they cannot attend live.

For more information, interested parties can access Replimune’s investor relations page or contact the provided investor and media inquiries for further details.

Replimune Group, Inc. (Nasdaq: REPL) is making significant strides in the biotechnology landscape with its innovative approach to cancer treatment through oncolytic immunotherapies. With its upcoming presentations at the Leerink Partners 2026 Global Healthcare Conference and the Jefferies 2026 Biotech on the Beach Summit, investors should closely monitor the company’s advancements and strategic insights.

Given the uniqueness of Replimune’s RPx platform, which utilizes a potent HSV-1 backbone to stimulate both local tumor destruction and systemic immune response, the company is positioned at the forefront of a promising frontier in cancer therapeutics. The potential combinatory effects of RPx with existing and novel treatment modalities could broaden its market appeal, attracting interest from a wide range of stakeholders in the oncology space.

Investors should consider several factors as they evaluate Replimune's growth trajectory. First, keep an eye on investor sentiment during the upcoming presentations, as management will likely discuss key clinical milestones and future development plans. The effectiveness of their messaging could influence stock performance and investor confidence moving forward.

Additionally, as the market for cancer therapies continues to expand, Replimune’s innovative platform could garner partnerships or collaborations, strengthening its financial backing and research capabilities. Analysts should assess the company's pipeline updates and any strategic partnerships mentioned during the conferences that might bolster their market positioning.

In conclusion, while Replimune demonstrates strong potential through its cutting-edge technology, investors should remain vigilant about market dynamics, clinical results, and competitive positioning in the oncology sector. Leveraging insights from the upcoming presentations could provide valuable indicators for future investment decisions.